Fam-trastuzumab deruxtecan-nxki (T-DXd) has demonstrated intracranial activity in small or retrospective cohorts of patients with HER2-positive metastatic breast cancer with stable or active brain metastases. At the ESMO Congress 2024, Lin et al presented the primary analysis of DESTINY-Breast12, the largest prospective study of T-DXd in this patient population.
